Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.97 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.76 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Palmitoyl-Carnitine SCHEMBL20608769 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNACYP1A2GMNN | |
| SCHEMBL21569424 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNACYP1A2GMNN | |
| SCHEMBL22392377 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNACYP1A2GMNN | |
| SCHEMBL25375657 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNACYP1A2GMNN | |
| SCHEMBL21114352 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNACYP1A2GMNN | |
| SCHEMBL25373349 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNACYP1A2GMNN | |
| SCHEMBL22392372 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNACYP1A2GMNN | |
| SCHEMBL22440886 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNACYP1A2GMNN | |
| SCHEMBL22440885 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNACYP1A2GMNN | |
| SCHEMBL19923326 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNACYP1A2GMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12370166-B2 | Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity | Epitracker, Inc. (US) | 2025-07-29 | — | — | US | claimed |
| US-20240307336-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | EPITRACKER INC (US) | 2024-09-19 | — | — | US | claimed |
| US-11992473-B2 | Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity | Epitracker, Inc. (US) | 2024-05-28 | — | — | US | claimed |
| WO-2023080939-A1 | PENTADECANOYLCARNITINE FOR TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | Epitracker, Inc. (US) | 2023-05-11 | — | — | WO | claimed |
| US-20230132955-A1 | PENTADECANOYLCARNITINE FOR TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | EPITRACKER INC (US) | 2023-05-04 | — | — | US | claimed |
| US-20220118269-A1 | MONITORING EFFICACY OF MAGNETIC AND ELECTRIC FIELDS USING BIOMARKERS | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2022-04-21 | — | — | US | claimed |
| EP-3908374-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | Epitracker, Inc. (US) | 2021-11-17 | — | — | EP | claimed |
| US-20210330734-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | Epitracker, Inc. | 2021-10-28 | — | — | US | claimed |
| EP-3796976-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | Epitracker, Inc. (US) | 2021-03-31 | — | — | EP | claimed |
| US-20210052535-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | Epitracker, Inc. | 2021-02-25 | — | — | US | claimed |
| WO-2020146263-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | Epitracker, Inc. (US) | 2020-07-16 | — | — | WO | claimed |
| US-20260137646-A1 | PENTADECANOYLCARNITINE FOR TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | EPITRACKER INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260137646-A1 | PENTADECANOYLCARNITINE FOR TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | EPITRACKER INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260077012-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | EPITRACKER INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | UNIV CALIFORNIA (US) | 2026-03-19 | — | — | US | disclosed |
| US-20210022368-A1 | REDUCED METHIONINE DIET FOR DOGS | MARS, INCORPORATED (US) | 2021-01-28 | — | — | US | disclosed |
| CN-112268962-A | Application of long-chain acyl carnitine as ischemic stroke biomarker | 南京医科大学 | 2021-01-26 | — | — | CN | disclosed |
| WO-2020154173-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | Epitracker, Inc. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-20200225213-A1 | COMPOSITIONS AND METHODS FOR DETECTING CARDIOTOXICITY | AGEX THERAPEUTICS, INC. (US) | 2020-07-16 | — | — | US | disclosed |
| WO-2020146263-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | Epitracker, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077012-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | CD4, COL2A1, MMP1 | MAPK1 1053/4885MAPT 175/4885LMNA 931/4885 |
| US-20260137646-A1 | PENTADECANOYLCARNITINE FOR TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | HTR6, HTR2A, OPRL1 | MAPK1 3010/4885MAPT 197/4885LMNA 3177/4885 |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | IDO1, INMT, IDO2 | MAPK1 3444/4885MAPT 1253/4885LMNA 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.